PatternsBioinformaticsPeer-reviewed journal article
New interpretable machine learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy
Evan Greene, Greg FinakiD, Leonard D’AmicoiD, Nina BhardwajiD, Candice D. ChurchiD, Chihiro MorishimaiD, Nirasha RamchurreniD, Janis Marie TaubeiD, Paul NghiemiD, Martin A. CheeveriD, Steven P. FlingiD, Raphaël GottardoiD
Abstract
High-dimensional single-cell cytometry is routinely used to characterize patient responses to cancer immunotherapy and other treatments. This has produced a wealth of datasets ripe for exploration but whose biological and technical heterogeneity make them difficult to analyze with current tools. We introduce a new interpretable machine learning method for single-cell mass and flow cytometry studies, FAUST, that robustly performs unbiased cell population discovery and annotation. FAUST processes data on a per-sample basis and returns biologically interpretable cell phenotypes that can be compared across studies, making it well-suited for the analysis and integration of complex datasets. We demonstrate how FAUST can be used for candidate biomarker discovery and validation by applying it to a flow cytometry dataset from a Merkel cell carcinoma anti-PD-1 trial and discover new CD4+ and CD8+ effector-memory T cell correlates of outcome co-expressing PD-1, HLA-DR, and CD28. We then use FAUST to validate these correlates in an independent CyTOF dataset from a published metastatic melanoma trial. Importantly, existing state-of-the-art computational discovery approaches as well as prior manual analysis did not detect these or any other statistically significant T cell sub-populations associated with anti-PD-1 treatment in either data set. We further validate our methodology by using FAUST to replicate the discovery of a previously reported myeloid correlate in a different published melanoma trial, and validate the correlate by identifying it de novo in two additional independent trials. FAUSTs phenotypic annotations can be used to perform cross-study data integration in the presence of heterogeneous data and diverse immunophenotyping staining panels, enabling hypothesis-driven inference about cell sub-population abundance through a multivariate modeling framework we call Phenotypic and Functional Differential Abundance (PFDA). We demonstrate this approach on data from myeloid and T cell panels across multiple trials. Together, these results establish FAUST as a powerful and versatile new approach for unbiased discovery in single-cell cytometry.
- organism: human
- assay: scRNA-seq
- assay: CITE-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: benchmarking
- research focus: database / resource
- approach: machine learning (classical)
- Citations
- 40
- FWCI
- 2.28
- Field percentile
- top 9%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Supervised discovery of interpretable gene programs from single-cell data
Russell Kunes, Thomas Walle, … Dana Pe’er·Nature BiotechnologyPeer-reviewed·Sep 21, 2023
- ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy
Ya‐Ru Miao, Qiong Zhang, … An‐Yuan Guo·Advanced SciencePeer-reviewed·Feb 11, 2020
- Scalable Multi-Sample Single-Cell Data Analysis by Partition-Assisted Clustering and Multiple Alignments of Networks
Ye Henry Li, Dangna Li, … Wing Hung Wong·PLoS Computational BiologyPeer-reviewed·Dec 27, 2017
- Agile workflow for interactive analysis of mass cytometry data
Julia Casado, Oskari Lehtonen, … Sampsa Hautaniemi·BioinformaticsPeer-reviewed·Oct 27, 2020
- A comprehensive single-cell breast tumor atlas defines cancer epithelial and immune cell heterogeneity and interactions predicting anti-PD-1 therapy response
L. Xu, K. N. Saunders, … I. S. Chan·bioRxiv·Aug 1, 2022
- Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy
F. J. Hartmann, J. Babdor, … S. C. Bendall·bioRxiv·Dec 13, 2018